Every round on record, with the sources behind each and the investors on them.
Cheiron sells a platform that connects and manages all aspects of drug development programs.
cheiron.bioLinkedInLos Altos, CaliforniaHealthtechFounded 202411-50 people
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed Verified against 3 sources | $8M | 2026-07-22 | Menlo Ventures | No recent discussion |
[ VERIFIED · CORRECTED ]1.00 read against 3 sources
[ BUILT WITH ]·[ SEARCH ]found by corroboration·[ SCRAPE ]3 pages read: en.wowtale.net, globenewswire.com, the-founders-corner.com | ||||
Cheiron builds an AI-native operating system and workbench that helps biopharma teams connect, query, verify, and manage the evidence, decisions, risks, and commitments across drug-development programs.
| Round | Amount | Announced | Lead |
|---|---|---|---|
| Seed | $4 million | 2025-08-04 | SK Networks |
Drug-development knowledge is scattered across papers, trials, filings, patents, datasets, and institutional memory, so teams spend substantial time reconstructing context before making decisions. Cheiron is betting that its Life Sciences Knowledge Graph can turn a drug program into a connected, auditable system; its latest disclosed traction was seven of Korea's top 10 biopharma companies as customers, while the $8 million seed is intended to expand the graph and clinical, regulatory, and strategic workflows.
Checked against 10 sources today
Via Alexandria from FullEnrich: founded, headcount, type, industry
Menlo Ventures